Raymond James resumed coverage of Regenxbio (RGNX) with an Outperform rating and $27 price target The firm expects the launch of Elevidys and permissive regulatory path primes RGX-202 for a similar accelerated approval on biomarker results, and says the failure of Pfizer’s program leaves a larger portion of the market. While Raymond James sees a limited role for subretinal gene therapy within neovascular retinal disease, it believes Regenxbio is well ahead of competitors and has less exposure to intraocular inflammation with potentially pivotal results coming the first half of 2026.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Biotech Alert: Searches spiking for these stocks today
- Morning Movers: H&E skyrockets following deal to be acquired by United Rentals
- RegenXBio Partners with Nippon Shinyaku on Gene Therapies
- Regenxbio, Nippon Shinyaku enter commercialization pact for RGX-121
- AbbVie, Regenxbio provide updates on ABBV-RGX-314 clinical program